Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).

Suppr

超能文献

作者信息

Denis L, Robinson M, Mahler C, Smith P, Keuppens F, De Moura J L, Bono A, Newling D, Sylvester R, De Pauw M

机构信息

A. Z. Middelheim, Antwerp, Belgium.

出版信息

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):951-9. doi: 10.1016/0960-0760(90)90449-u.

DOI:10.1016/0960-0760(90)90449-u

PMID:2149508

Abstract

A total of 327 patients with metastatic prostate cancer have been randomized to either orchidectomy or treatment with goserelin (Zoladez) 3.6 mg depot preparation combined with flutamide (Eulexin) 250 mg t.i.d. in a phase III study (EORTC 30853). A small but statistically significant difference in time to subjective and objective progression of disease was found in favour of the combination treatment. However, time from objective progression to death was longer in the group initially allocated to orchidectomy. Thus no difference was found in overall survival between the two treatment groups. The clinical significance of these differences requires further follow up and analysis.

摘要